A Lethal Elixir, The Urgent Imperative for Quality Control in India’s Pharmaceutical Ascent

The vision of an “Atmanirbhar Bharat” (Self-Reliant India) is a powerful and aspirational goal for the nation, promising economic sovereignty and global leadership. In few sectors is this ambition more pronounced—or more precarious—than in the Indian pharmaceutical industry. Dubbed the “Pharmacy of the World,” India supplies a vast portion of the globe’s generic medicines, vaccines, and essential drugs, particularly to developing nations. This reputation is a monumental asset, built on decades of industrial growth and scientific prowess. However, this hard-earned standing is being systematically undermined by a persistent and deadly foe: the scourge of substandard and poor-quality drugs. Recent tragedies, including the deaths of at least 14 children in Rajasthan and Madhya Pradesh linked to a contaminated cough syrup, have cast a harsh and unforgiving light on the cracks in the system. These are not isolated incidents but symptoms of a deeper malaise. The pursuit of a self-reliant India is a worthy ideal, but it is an empty one if not built upon an unshakeable foundation of quality control, regulatory rigor, and a zero-tolerance policy for negligence. The time for excuses has passed; for the sake of public health and national reputation, firms that manufacture poor-quality drugs must face swift and severe consequences.

The Coldrif Case: A Microcosm of Systemic Failure

The recent case involving the cough syrup “Coldrif” serves as a chilling case study of how regulatory failures can have fatal consequences. The sequence of events reveals a disturbing narrative:

The Tragedy: Reports emerged of children in Rajasthan and Madhya Pradesh dying under mysterious circumstances, with a commonly prescribed cough syrup, Coldrif, being a suspected culprit.
Contradictory Findings: The Union Health Ministry initially ruled out the presence of diethylene glycol (DEG) in samples tested from these states. However, in a parallel investigation, the Tamil Nadu Drugs Control Department found DEG levels above permissible limits in samples of the same syrup lifted within their state.
The Root Cause: The Tamil Nadu report went beyond mere contamination detection. It documented several non-compliance factors with Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) at the manufacturing facility. Crucially, it found that the contaminated batch was manufactured using “non-pharmacopoeial grade propylene glycol” as an excipient (an inactive substance that serves as a vehicle for the active drug).

This last point is the heart of the failure. Pharmacopoeial grade ingredients are certified for purity and safety for human consumption. Using an industrial-grade alternative is a catastrophic cost-cutting measure. Non-pharmacopoeial grade propylene glycol is often contaminated with DEG and ethylene glycol—substances known to be potent nephrotoxins, causing acute kidney failure and death, especially in small children.

This case highlights a dangerous patchwork of enforcement. The fact that one state agency found a deadly contaminant while central tests initially did not points to potential inconsistencies in sampling, testing protocols, or laboratory competence. It reveals a system where compliance is not uniform and where deadly lapses can slip through the cracks until it is too late.

The Global Stain: A Pattern of Lethal Exports

The Coldrif incident is not an anomaly. It is part of a distressing pattern that has severely damaged India’s international standing. In recent years, Indian-manufactured cough syrups have been linked to hundreds of child deaths abroad.

The Gambia Tragedy (2022): The World Health Organization (WHO) issued an alert linking cough syrups made by Maiden Pharmaceuticals in India to the deaths of at least 70 children in The Gambia from acute kidney injury. The products were found to contain “unacceptable amounts” of DEG and ethylene glycol.
Uzbekistan Tragedy (2022): At least 19 children died in Uzbekistan after consuming a cough syrup, Doc-1 Max, manufactured by Marion Biotech in India. Laboratory analysis confirmed the presence of ethylene glycol.
Cameroon and Liberia: Similar alerts were issued for other Indian-made syrups found to be contaminated in these African nations.

These international incidents have triggered a crisis of confidence. They have led to import bans, heightened scrutiny from foreign regulators, and a global questioning of the “Made in India” label in the pharmaceutical sector. The term “Pharmacy of the World” is at risk of being redefined from a badge of honor to a warning label. Each such event is not just a public health disaster for the affected countries but a direct threat to a $50 billion export industry that India can ill afford to jeopardize.

The Regulatory Framework: Strong on Paper, Weak in Execution

India is not lacking in regulations. The Drugs and Cosmetics Act, 1940, and the rules under it, particularly the recently revised Schedule M, provide a comprehensive framework for ensuring drug quality. Schedule M outlines detailed requirements for Good Manufacturing Practices, covering everything from factory premises and equipment to quality control and documentation.

The problem lies in implementation and enforcement. Key weaknesses include:

Insufficient Inspections: There is a critical shortage of drug inspectors relative to the vast number of manufacturing units in the country. This leads to infrequent inspections and a lack of surprise checks, allowing companies to prepare for audits and conceal malpractices.
Inconsistent Enforcement Across States: Drug regulation in India is a shared responsibility between the central and state governments. This can lead to a lack of standardization, with some states having robust control departments and others being understaffed and less rigorous.
Lax Penalties and Legal Delays: Even when violations are detected, the penalties have historically been insufficient to act as a deterrent. The process of canceling a manufacturing license is often slow and mired in legal challenges, allowing rogue manufacturers to continue operating.
Supply Chain Vulnerabilities: The failure to properly vet raw material suppliers, as seen in the Coldrif case where a non-pharmacopoeial grade ingredient was used, is a major vulnerability. The entire supply chain, from the chemical supplier to the finished product, must be subject to rigorous oversight.

The Path to Redemption: Building an Iron-Clad Quality Regime

To salvage its reputation and, more importantly, to protect human lives, India must undertake a fundamental overhaul of its pharmaceutical regulatory system. The following steps are non-negotiable:

Zero-Tolerance Policy and Hawk-Like Monitoring: The government must adopt an unequivocal zero-tolerance stance towards quality violations. This requires a significant strengthening of the Central Drugs Standard Control Organisation (CDSCO) and state agencies. The number of drug inspectors must be increased, and they must be equipped with modern testing equipment and empowered to conduct frequent, unannounced inspections.
Mandatory and Retrospective Testing of Raw Materials: Every batch of raw material, especially high-risk solvents like propylene glycol and glycerol, must be tested for contaminants like DEG and ethylene glycol before being used in production. This testing should be mandatory and documented as part of the batch record.
Swift and Exemplary Punishment: The CDSCO’s recommendation to cancel the manufacturing license of the firm behind Coldrif is a step in the right direction. This must become the norm, not the exception. Criminal charges should be pursued against company executives in cases of gross negligence leading to death. The message must be clear: manufacturing substandard drugs is not a regulatory slip but a criminal act.
Leveraging Technology for Transparency: Implementing track-and-trace systems, like QR codes on drug packaging, can help authenticate products and combat counterfeit and substandard drugs. A centralized digital database for drug approvals, inspections, and violations can improve coordination between central and state authorities.
Cultural Shift Within the Industry: Beyond regulation, there must be a cultural shift within the pharmaceutical industry itself. The pursuit of profit cannot override the sacred duty to patient safety. Industry bodies must champion a culture of quality, where adherence to GMP is a source of pride and competitive advantage, not a burdensome compliance cost.

The Stakes: More Than Just Reputation

The stakes extend far beyond export revenues and national pride. At its core, this is a matter of public trust and fundamental human safety. When a patient takes a medicine, they do so with the implicit trust that it is safe and effective. This trust is the bedrock of the entire healthcare system. Every incident of contamination shatters this trust, not just in a single product, but in the entire medical establishment.

For India, the choice is stark. It can continue on its current path, where periodic tragedies trigger temporary crackdowns, only for the cycle to repeat itself. Or, it can seize this moment of crisis as an opportunity for transformation. It can build a regulatory ecosystem that is the global gold standard—feared by negligent manufacturers and trusted by patients and governments worldwide.

A true “Atmanirbhar Bharat” in pharmaceuticals is not one that merely produces a high volume of drugs. It is one that produces drugs of uncompromising quality and safety. It is an India where the “Made in India” stamp on a medicine vial is a universal symbol of reliability and trust. Achieving this requires more than revised schedules and ministerial directives; it requires an unwavering political will, robust institutional capacity, and an industry-wide ethical awakening. The lives of children in India, The Gambia, and everywhere else Indian medicines reach, depend on it.

Q&A: Delving Deeper into India’s Pharmaceutical Quality Crisis

Q1: What are diethylene glycol (DEG) and ethylene glycol, and why are they so deadly in cough syrup?

A1: Diethylene glycol (DEG) and ethylene glycol are industrial solvents and antifreeze agents. They are toxic to humans and should never be consumed. When ingested, the body metabolizes them into compounds that cause severe metabolic acidosis (a dangerous drop in blood pH) and are profoundly nephrotoxic, meaning they destroy the cells of the kidneys. This leads to acute kidney failure, which is often fatal, especially in children whose smaller body size makes them more vulnerable to even small doses. Their use in medicine is always the result of a catastrophic failure—typically, the substitution of safe, pharmaceutical-grade propylene glycol or glycerol with a much cheaper, contaminated industrial grade.

Q2: The article mentions “Schedule M.” What is it, and how can its revision help?

A2: Schedule M of the Drugs and Cosmetics Rules lays down the detailed Good Manufacturing Practices (GMP) requirements for pharmaceutical products in India. Its recent revision aims to align Indian standards more closely with global best practices (like those of the WHO). Key improvements include stricter requirements for quality control, infrastructure, product validation, and stability testing. If implemented and enforced rigorously, it can compel manufacturers to upgrade their facilities, processes, and documentation, creating a systemic barrier against the kind of shoddy practices that lead to contamination.

Q3: Why is there often a discrepancy between findings from different state drug control departments and the central authority?

A3: This discrepancy points to several systemic issues:

Resource Disparity: Some state drug control departments (like Tamil Nadu’s) are well-funded and equipped with advanced laboratories, while others may lack the resources, trained personnel, or modern equipment for accurate testing.
Sampling Issues: The batch of drugs tested, the point in the supply chain from which the sample was taken, and the sampling procedure itself can vary, leading to different results.
Methodology: While there are standard testing protocols, slight variations in methodology or human error can sometimes yield conflicting results.
This inconsistency undermines the entire regulatory framework and highlights the need for a centralized, highly competent authority to oversee and standardize drug testing nationwide.

Q4: Beyond punishment, what proactive steps can the government take to prevent such incidents?

A4: Proactive measures are crucial and include:

Risk-Based Inspections: Prioritizing inspections of manufacturers of high-risk products like liquid syrups, pediatric medicines, and sterile injectables.
Supply Chain Audits: Mandating that manufacturers audit and qualify their raw material suppliers, ensuring they provide certificates of analysis and adhere to quality standards.
Whistleblower Programs: Establishing secure and anonymous channels for employees within pharmaceutical companies to report quality lapses and safety concerns without fear of retribution.
Public Disclosure: Maintaining a transparent, public database of manufacturing licenses, inspection reports, and regulatory actions to empower consumers and healthcare providers.

Q5: How does this quality crisis impact India’s broader economic and geopolitical goals?

A5: The impact is profound and multi-faceted:

Economic Damage: The pharmaceutical industry is a major exporter and employer. A loss of international trust can lead to import bans, canceled contracts, and a long-term decline in market share, costing billions of dollars and thousands of jobs.
Geopolitical Leverage: India’s role as the “Pharmacy of the Global South” is a significant source of soft power and diplomatic influence, especially in Africa and Latin America. This credibility is severely damaged by lethal product exports.
“Atmanirbhar Bharat” Setback: The vision of a self-reliant India is undermined if the world perceives “Made in India” as a mark of poor quality and danger. Building a brand synonymous with reliability is essential for the success of this national project.

A Lethal Elixir, The Urgent Imperative for Quality Control in India’s Pharmaceutical Ascent